Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Recent Advances and Emerging Therapeutic Approaches for the Treatment of...
share announcement

Recent Advances and Emerging Therapeutic Approaches for the Treatment of Heart Failure

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 27 April 2024 | Viewed by 2021

Special Issue Editors

Prof. Dr. Nikolaos K. Fragakis

E-Mail Website
Guest Editor
Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
Interests: arrhythmia disorders; ablation; cardiac devices; syncope; heart failure
Special Issues, Collections and Topics in MDPI journals
Dr. Efstratios Karagiannidis

E-Mail Website
Guest Editor
Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
Interests: myocardial infarction; heart failure; coronary artery disease; atrial fibrillation

Special Issue Information

Dear Colleagues,

Heart failure (HF) has been described as a growing epidemic, due to the ageing population as well as the improvement in survival after its diagnosis. Despite striking advances in recent years, considerable uncertainties still surround its pathophysiologic mechanisms and optimal management. This Special Issue of the Journal of Clinical Medicine aims to highlight the recent advances and the emerging therapeutic approaches in the field of HF management. Researchers will have the opportunity to publish both original research and review articles related to contemporary findings about both invasive and non-invasive treatment of HF across the spectrum of ejection fraction. This Special Issue aims to contribute to the implementation of novel therapeutic approaches regarding holistic, personalized, and patient-centered management of HF in everyday clinical practice.

Prof. Dr. Nikolaos K. Fragakis
Dr. Efstratios Karagiannidis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • heart failure with reduced ejection fraction
  • heart failure with preserved ejection fraction
  • cardiomyopathies
  • therapeutic approaches

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 952 KiB  
Article
Systemic Congestion as a Determinant of Efficacy in Adaptive Servo-Ventilation Therapy: A Retrospective Observational Study
by Yu Nomoto, Teruhiko Imamura and Koichiro Kinugawa
J. Clin. Med. 2024, 13(3), 674; https://doi.org/10.3390/jcm13030674 - 24 Jan 2024
Viewed by 480
Abstract
Background: The optimal criteria for patient selection in the context of adaptive servo-ventilation (ASV) therapy remain a subject of ongoing investigation. We postulate that baseline plasma volume, assessable through several straightforward clinical parameters, might be correlated with a more pronounced reduction in plasma [...] Read more.
Background: The optimal criteria for patient selection in the context of adaptive servo-ventilation (ASV) therapy remain a subject of ongoing investigation. We postulate that baseline plasma volume, assessable through several straightforward clinical parameters, might be correlated with a more pronounced reduction in plasma B-type natriuretic peptide (BNP) levels following mid-term ASV therapy. Methods: We included patients diagnosed with congestive heart failure who had received continuous ASV therapy for a minimum of three months. The primary outcome of interest was the extent of decline in logarithmically transformed plasma BNP levels, defined as a decrease of more than 0.10 during the 3-month ASV treatment period. Results: A total of 66 patients were included in the study. The median age of the cohort was 66 years, with 53 patients (80%) being male. The median plasma volume status at baseline was −16.9%, and patients were categorized into two groups based on this median value. Patients with elevated baseline plasma volume status experienced a statistically significant reduction in plasma BNP levels (p = 0.016), whereas those with lower plasma volume exhibited no significant change in BNP levels (p = 0.23). A higher baseline plasma volume status was independently associated with a significant reduction in plasma BNP levels, with an adjusted odds ratio of 1.036 (95% confidence interval: 1.01–1.07, p = 0.032). Conclusions: The presence of systemic congestion at baseline, quantified by the estimated plasma volume status, may serve as a crucial determinant of the efficacy of ASV therapy, leading to improvements in plasma BNP levels among patients suffering from congestive heart failure. Full article
(This article belongs to the Special Issue Recent Advances and Emerging Therapeutic Approaches for the Treatment of Heart Failure)
►▼ Show Figures

Figure 1

Other

Jump to: Research

16 pages, 2601 KiB  
Systematic Review
Intravenous Landiolol for Rate Control in Supraventricular Tachyarrhythmias in Patients with Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis
by Athina Nasoufidou, Andreas S. Papazoglou, Panagiotis Stachteas, Efstratios Karagiannidis, Athanasios Samaras, Sophia Alexiou, Michail-Angelos Mourtzos, George Kassimis and Nikolaos Fragakis
J. Clin. Med. 2024, 13(6), 1683; https://doi.org/10.3390/jcm13061683 - 14 Mar 2024
Viewed by 544
Abstract
Background: This systematic review explores the effects of landiolol administration in individuals presenting with supraventricular tachyarrhythmia (SVT) and concurrent left ventricular dysfunction, without being septic or in a peri-operative period. Methods: We systematically searched PubMed, Cochrane, Web of Science, and Scopus databases, retrieving [...] Read more.
Background: This systematic review explores the effects of landiolol administration in individuals presenting with supraventricular tachyarrhythmia (SVT) and concurrent left ventricular dysfunction, without being septic or in a peri-operative period. Methods: We systematically searched PubMed, Cochrane, Web of Science, and Scopus databases, retrieving a total of 15 eligible studies according to prespecified eligibility criteria. Results: Patients treated with landiolol experienced a substantial reduction in heart rate (HR) (mean HR reduction: 42 bpm, 95% confidence intervals (CIs): 37–47, I2 = 82%) and were more likely to achieve the target HR compared to those receiving alternative antiarrhythmic therapy (pooled odds ratio (OR): 5.37, 95% CIs: 2.87–10.05, I2 = 0%). Adverse events, primarily hypotension, occurred in 14.7% of patients receiving landiolol, but no significant difference was observed between the landiolol and alternative antiarrhythmic receiving groups (pooled OR: 1.02, 95% CI: 0.57–1.83, I2 = 0%). No significant difference was observed between the two groups concerning sinus rhythm restoration (pooled OR: 0.97, 95% CI: 0.25–3.78, I2 = 0%) and drug discontinuation due to adverse events (pooled OR: 5.09, 95% CI: 0.6–43.38, I2 = 0%). Conclusion: While further research is warranted, this systematic review highlights the potential benefits of landiolol administration in the management of SVTs in the context of left ventricular dysfunction. Full article
(This article belongs to the Special Issue Recent Advances and Emerging Therapeutic Approaches for the Treatment of Heart Failure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: mechanical support in advanced heart failure
Authors: Stergios Tzikas
Affiliation: Department of Cardiology, Aristotle University of Thessaloniki, Ippokrateio Hospital, Thessaloniki, Greece

Title: the value of mRNAs as biomarkers in heart failure to possibly guide diagnosis and treatment
Authors: Stergios Tzikas
Affiliation: Department of Cardiology, Aristotle University of Thessaloniki, Ippokrateio Hospital, Thessaloniki, Greece

Back to TopTop